已核实 DOI PubMed 相关产品: 1

m6A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes

Journal 2020 · IF 7.051 · 发表于 2020 年 11 月 5 日
作者: Yuhuan Li,Qingyang Zhang,Guanshen Cui,Fang Zhao,Xin Tian,Bao-Fa Sun,Ying Yang,Wei Li
阅读全文 在 PubMed 查看

摘要

N 6 -methyladenosine (m 6 A) is one of the most abundant modifications on mRNAs and plays important roles in various biological processes. The formation of m 6 A is catalyzed by a methyltransferase complex (MTC) containing a key factor methyltransferase-like 3 ( Mettl3 ). However, the functions of Mettl3 and m 6 A modification in hepatic lipid and glucose metabolism remain unclear. Here, we showed that both Mettl3 expression and m 6 A level increased in the livers of mice with high fat diet (HFD)-induced metabolic disorders. Overexpression of Mettl3 aggravated HFD-induced liver metabolic disorders and insulin resistance . In contrast, hepatocyte-specific knockout of Mettl3 significantly alleviated HFD-induced metabolic disorders by slowing weight gain, reducing lipid accumulation, and improving insulin sensitivity. Mechanistically, Mettl3 depletion-mediated m 6 A loss caused extended RNA half-lives of metabolism-related genes, which consequently protected mice against HFD-induced metabolic syndrome. Our findings reveal a critical role of Mettl3-mediated m 6 A in HFD-induced metabolic disorders and hepatogenous diabetes.

本研究中使用的阿拉丁产品

1 款产品在本文中被引用